ThermoGenesis Holdings, Inc. · OTC:THMO
ThermoGenesis — Cesca Therapeutics — BIO Investor Forum, San Francisco 2019
25 slides from ThermoGenesis's conference presentation, Oct 22, 2019

Slide 1: BIO Investor Forum, San Francisco
Exhibit 99.1. NASDAQ: KOOL Therapeutics ae —— _— BIO Investor Forum, San Francisco (Oct 22, 2019) Jeff Cauble, Vice President of Finance 1 | NASDAQ: KOOL

Slide 2: Disclosure and Forward Looking Statement
| Disclosure and Forward Looking Statement This presentation includes statements of future expectations and other forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current

Slide 3: Company Overview
i} | Company Overview Rancho Cordova, CA Corporate Structure ESCA “ ThemoGenesis® * CARTXpress Bio, 3 | NASDAQ: KOOL Totipdient oC Company currently offers a full suite of products: Corporate headquarters located in a 28,000 sq.ft. facility in Rancho Cordova, CA. Founded in 1986, company isa leading

Slide 4: Key Financial Performance
4 Key Financial Performance — Steady improvement in financial results since 2018 Revenue Gross Profit {Sin rilions) {Sin milion) $5.0 $4.3 $2.5 $4.0 B17 $0 $2.0 $3.0 i 0 $15 $2.0 i 2 $1.0 $1.0 $0.5 $0.0 $0.0 SL, (meee Lamia avis Namean, jeer musa 21a? wIBG3 wr ~mVAI mO2 Operating Expenses (5 inmilli

Slide 5: Revenue Growth & Cost Reduction Strategy
| Revenue Growth & Cost Reduction Strategy — Transforming from a medical device company to a leading solution provider for cell based therapies Pas’ wo (2) Years Cesca completes [FG iaunchedcAR-] |” Cesca completes 76 completes plsekis TG launched = ‘Txpress™ reorganization to construction ofin- 76

Slide 6: Adjusted EBITDA by Quarter
$0.5 Adjusted EBITDA by Quarter 2018 Q1—2019 Q2 (Sinmilions) $0.0 $0.1 -$0.5 -$1.0 “$15 -$2.0 “$2.5 -$2.9 -$3.0 -$3.0 -$3.5 Approaching Inflection Point 6 | NASDAQ: KOOL Adjusted EBITDA Steadily Increased — Result of combined measures to increase revenue and reduce costs Key metric used by the Compa

Slide 7: Our Future: Enabling Next-Generation Cell Therapies
ym) Our Future: Enabling Next-Generation Cell Therapies — Genetically modified autologous cell therapies Chimeric Antigen ReceptorT Cells (CAR-T) Engineered CD34 Hematopoietic Stem Cells INDICATIONS + Acute lymphoblastic leukemia + Diffuse large B-cell lymphoma + Multiple myeloma + Other blood cance

Slide 8: Cell & Gene Therapy Target Market
5 | Cell & Gene Therapy Target Market — Cell & gene therapies are an emerging field with a rapid increase in the number of clinical trials globally Worldwide Trials + 800+ Clinical Trials + 900+ Companies Global Market * Global regenerative medicine ‘and cell therapy market to grow to USS 67.6 Billi

Slide 9: Critical Unmet Needs for Manufacturing Cell Therapies
Critical Unmet Needs for Manufacturing Cell Therapies — Traditional process involves the use of ficoll and magnetic beads that is labor-intensive and time consuming CAR-T Manufacture Cost Average manufacture cost for ach dose of CAR-Ttherapeutics: > $100,000 USD I Scaling up production (33%) fl] Rei

Slide 10: CAR-TXpress Cell Processing Platform
0 CAR-TXpress™ Cell Processing Platform —A modular designed, semi-automated, closed system for large scale cellular manufacturing Cesca’s technology reduces cell selection time from eight hours to two hours WE Saveson cGMP ML Savesonstafftme IML Increases throughput per clean room wR wes cel recover

Slide 11: Our Key Technology
11 Our Key Technology — Proprietary, new approach for separating cells from blood using a “bubble” technology Targetcells w/beads Non-Targetcells w/o beads Traditional Technology: Magnetic Activated Cell Sorting (MACS) 41 | NASDAQ: KOOL 4 % ‘what iets: ThermoGenesis¥ + BACS uses microscopic bubbles

Slide 12: X-Series Products from CAR-TXpress Platform
ip] | X-Series® Products from CAR-TXpress™ Platform — High efficiency processing, washing and formulation of various cellular products X-LAB Harvests & purifies MNCs from blood, bone marrow or leuka- pheresis, depleting up to: 99% ‘of RBCS, 70% of GRNS, 85% of PLTS, and excess plasma volume. X-WASH

Slide 13: Global Distribution Agreement
Global Distribution Agreement — Partnership with a major global company to distribute X-Series products worldwide Key Terms for Agreement: + $2M upfront license fee (Received Oct. 1) * Covers X-Series™ products * Worldwide exclusive rights, excluding China for the first two years * Five year term, r

Slide 14: A Full Product Line for Automated Cellular Processing
A Full Product Line for Automated Cellular Processing — From stem cell banking, to point-of-care clinical applications, to large scale cellular processing 1. AutoXpress® Platform for Stem Cell Banking 2. POCXpress™ Platform for Point-of-Care Application 3.CAR-TXpress™ Platform for Large Scale Cell P

Slide 15: AXP: Leading Automated Technology for Cord Blood Banks
15 AXP®: Leading Automated Technology for Cord Blood Banks — Fully automated system for the isolation of stem cells from cord blood with superior performance udes top public and private cord blood ba ridwide NYBC National Cord Blood Program AXP Processing Results: N=34,011 CBUs Cryobank Company cord

Slide 16: BioArchive: Global Market Penetration
BioArchive®: Global Market Penetration — 300+ BioArchive Systems, 129 sites in 37 countries 2 ce : e e ° “ e 16 | NASDAQ: KOOL { BioArchive® has been ) used in 4 BLAs approved by FDA 4New York Blood Center MDAnderson ‘Ganeer Center Cleveland Clinic ThermoGenesis® | SERS

Slide 17: Cesca/ThermoGenesis' Future Growth Strategy
Cesca/ThermoGenesis’ Future Growth Strategy — Transforming from a medical device company to a leading solution provider for cell therapies 2019 2020 2024 2022 2023 2024 17 | NASDAQ: KOOL ThermoGenesis® | SEESCA

Slide 18: Cesca CMO/CDMO Joint Venture — ImmuneCyte
Cesca CMO/CDMO Joint Venture — ImmuneCyte — ImmuneCyte Life Sciences, Inc. is a joint venture between Healthbanks Biotech (USA) and Cesca ImmuneCyte is among the first cell banks in the U.S. to provide clients with the opportunity to bank their own healthy immune cells for future use as a resource f

Slide 19: Addressing Critical Unmet Needs in Cell & Gene Therapy
Addressing Critical Unmet Needs in Cell & Gene Therapy —ImmuneCyte is among the first cell banks in the U.S. that provides immune cell banking services Immunotherapy, such as CAR-T cell, has become one of the most promising methods for treating cancer. However, a significant portion (can be as high

Slide 20: ImmuneCyte's Easy Banking Procedures
ImmuneCyte’s Easy Banking Procedures — Preserving one’s healthy and unaffectedimmune cells with easy steps Thaw and used for caR-Tee Proprietary CAR-TepressPsform production when needed Immunotherapies 20 | NASDAQ: KOOL Immune:Cyte | SEESCA

Slide 21: CAR-TXpress Platform's Competitive Advantages
21 CAR-TXpress Platform’s Competitive Advantages — Separates multi-components simultaneously through a GMP compliant, automated process with high throughput and reduced processing times CAR-TXpress™ Multi-Component Automated Separation& Storage Capability BioArchive® \ a Summary of Competitive Advan

Slide 22: A Significant Market Opportunity Exceeding $30B USD
22 A Significant Market Opportunity Exceeding $30B USD' — The history of cord blood banking vs. immune cell banking shows large market potential Fig 1. Growth of banked cord bloodunits since 1992 First demonstration of First cord blood banking = clinicalusetulness service established [= Pisioystersn

Slide 23: Experienced Leadership Team
23 | Experienced Leadership Team £ aa 23 | NASDAQ: KOOL Chris Xu, PhD/MBA, Chairman, President and Chief Executive Officer 20+ years in life sciences and pharmaceutical industry Founder of the Boyalife Group; fostered more than 20+ private public companies Haihong Zhu, President of ThermoGenesis Cor

Slide 24: Investment Values and Peer Group Comparison
yyy) Investment Values and Peer Group Comparison — With a strong cash position heading into 2020, Cescais at an inflection point moving forward Cash Position Scientific Tool and Service Companies (in millions) in Cell & Gene Therapy Field $5.0 $4.5 Company Cesca Cryoport | Biolife $4.0 Ticker (Nasda

Slide 25: Company Contact
Company Contact: Cesca Therapeutics Inc. Wendy Samford 916-858-5191 ir@cescatherapeutics.com 25 | NASDAQ: KOOL Investor Contact: Rx Communications Paula Schwartz 917-322-2216 pschwartz@niir.com For more information: Cesca Therapeutics Inc., visit: ThermoGenesis Corp., visit: ww.th el A ThermoGenesis
Source: SEC EDGAR · 8-K filed Oct 22, 2019
More decks from ThermoGenesis Holdings, Inc.
H. C. Wainwright BioConnect Conference 202224 slides · Jan 10, 2022
H.C. Wainwright 23rd Annual Global Investment Conference 202119 slides · Sep 15, 2021
Corporate Update (May 2020)18 slides · May 14, 2020
Q3 2019 Earnings Presentation26 slides · Nov 20, 2019
Cesca Therapeutics — HC Wainwright 21st Annual Global Investment Conference (September 2019)20 slides · Sep 11, 2019
Cesca Therapeutics — BIO CEO & Investor Conference 201921 slides · Feb 13, 2019